PSC
EGRX

Piper Sandler & Co’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Piper Sandler & Co’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$7K Buy
+100
New +$5.54K 0.01% 11
2014
Q3 		– Sell
-1,277
Closed -$18K – 171
2014
Q2 		$18K Buy
+1,277
New +$14.6K 0.01% 109

Other funds holding EGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Piper Sandler & Co's EGRX Position: Q3 2016 in Review

Piper Sandler & Co opened a new position in Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2016: 100 shares worth $7K. The stake represents 0.01% of the portfolio and ranks #11 among its holdings. This is a return to the name: Piper Sandler & Co previously reported a position in EGRX as recently as Q2 2014.

Piper Sandler & Co first reported a position in EGRX in Q2 2014 and has held it in 2 quarters since. The position peaked at $18K in Q2 2014. 137 funds tracked by Wall St. Rank hold EGRX as of Q3 2016.

  • Piper Sandler & Co held 100 shares of Eagle Pharmaceuticals, Inc. worth $7K as of Q3 2016.
  • Eagle Pharmaceuticals, Inc. was a new Piper Sandler & Co position in Q3 2016.
  • Eagle Pharmaceuticals, Inc. made up 0.01% of Piper Sandler & Co's portfolio in Q3 2016, its #11 holding.
  • Piper Sandler & Co first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2014 and has held it in 2 quarters since.
  • Piper Sandler & Co's Eagle Pharmaceuticals, Inc. position peaked at $18K in Q2 2014.
  • 137 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2016.

Based on Piper Sandler & Co's 13F filing for Q3 2016, filed 14 Nov 2016.